Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Frontiers in Endocrinology|November 1, 2024
Characterization of GABAergic marker expression in prefrontal cortex in dexamethasone induced depression/anxiety modelLing Hu, Ming-Jing Qiu, Wen-Juan Fan, et al.
Asian Journal of Andrology|October 3, 2023
scRNA-seq reveals that origin recognition complex subunit 6 regulates mouse spermatogonial cell proliferation and apoptosis via activation of Wnt/β-catenin signalingShi-Wei Liu, Jia-Qiang Luo, Liang-Yu Zhao, et al.
Iscience|July 1, 2024
GSK2334470 attenuates high salt-exacerbated rheumatoid arthritis progression by restoring Th17/Treg homeostasisQian Mo, Mansoor Bolideei, Shan-Jie Rong, et al.
Cell Metabolism|September 18, 2024
PDIA3 defines a novel subset of adipose macrophages to exacerbate the development of obesity and metabolic disordersJia-Hui Luo, Fa-Xi Wang, Jia-Wei Zhao, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 1, 2024
PDIA3 orchestrates effector T cell program by serving as a chaperone to facilitate the non-canonical nuclear import of STAT1 and PKM2Chun-Liang Yang, Fa-Xi Wang, Jia-Hui Luo, et al.
Quantitative Imaging in Medicine and Surgery|September 14, 2018
The protocol for the Prospective Urban Rural Epidemiology China Action on Spine and Hip status studyKai Li, Yong Zhang, Ling Wang, et al.
NPJ Breast Cancer|December 2, 2021
The tale of TILs in breast cancer: A report from The International Immuno-Oncology Biomarker Working GroupKhalid El Bairi, Harry R Haynes, Elizabeth Blackley, et al.
The Journal of Pathology|March 5, 2020
The path to a better biomarker: application of a risk management framework for the implementation of PD-L1 and TILs as immuno-oncology biomarkers in breast cancer clinical trials and daily practicePaula I Gonzalez-Ericsson, Elisabeth S Stovgaard, Luz F Sua, et al.
Pageof 7